Literature DB >> 27460457

Long-term survival after chronic subdural haematoma.

Appukutty Manickam1, Laurence A G Marshman2, Ross Johnston3.   

Abstract

Outcome after chronic subdural haematoma (CSDH) is invariably assumed favourable: however, little data regarding long term survival (LTS) exists. One study reported excess mortality restricted to year 1, but with expected actuarial rates thereafter. We aimed to determine LTS after CSDH in a retrospective analysis relative to actuarial data from age-matched controls. Data was obtained in n=155, (M:F 97:58, 69.3±2.3years). Follow-up maxima was 14.19years (mean: 4.02±3.07years, median: 5.2years). Mortality in-hospital, at 6months, 1year, 2years and 5years was n=13 (8.39%), n=22 (14.19%), n=31 (20.35%), n=42 (27.1%) and n=54 (34.84%). LTS was significantly worse than controls (5.29±0.59years vs. 17.74±1.8years, hazard ratio [HR]: 3.52, P<0.0001). Death most frequently related to pneumonia/sepsis and ischemic heart disease (IHD). Median modified Rankin score (mRS) in those discharged home (n=94, 60.65%) was 2 [IQR: 1-3]. Discharge mRS in those who died at 6months, 1year, 2years and 5years was 5 [IQR: 3-6], 5 [IQR: 4-6], 3 [IQR: 1-3], 4 [IQR: 2-5]. Discharge mRS was significantly worse with year 1 mortality (P=0.014). LTS related to discharge mRS (HR: 37.006, P<0.001), post-operative motor-score (HR: 0.581, P=0.0026), IHD (HR: 5.186, P=0.005), warfarin-use (HR: 5.93, P=0.036) and dementia (HR: 5.39, P=0.031). No long term recurrences (LTR) were recorded. Although most were discharged home with mRS=2, LTS was markedly less than previously reported: peers lived 12.4years longer. Although greater in year 1, excess mortality was not restricted to year 1, but continued throughout prolonged follow-up. LTS related to discharge disability and dependence, and co-morbid risk factors for cerebral atrophy. No LTR suggests that, once ultimately closed, the 'subdural space' remains closed. CSDH patients represent a vulnerable group who require continued long-term medical surveillance. Crown
Copyright © 2016. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic subdural haematoma; Long-term survival; Modified Rankin scale

Mesh:

Year:  2016        PMID: 27460457     DOI: 10.1016/j.jocn.2016.05.026

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  10 in total

Review 1.  [Chronic subdural hematoma in the elderly].

Authors:  T A Juratli; J Klein; G Schackert
Journal:  Chirurg       Date:  2017-02       Impact factor: 0.955

2.  Mortality after chronic subdural hematoma is associated with frailty.

Authors:  Jurre Blaauw; Bram Jacobs; Heleen M den Hertog; Niels A van der Gaag; Korné Jellema; Ruben Dammers; Kuan H Kho; Rob J M Groen; Joukje van der Naalt; Hester F Lingsma
Journal:  Acta Neurochir (Wien)       Date:  2022-09-29       Impact factor: 2.816

Review 3.  Chronic Subdural Hematoma.

Authors:  Hussam A Hamou; Hans Clusmann; Jörg B Schulz; Martin Wiesmann; Ertunc Altiok; Anke Höllig
Journal:  Dtsch Arztebl Int       Date:  2022-03-25       Impact factor: 8.251

Review 4.  Chronic Subdural Hematoma in Elderly Patients: Is This Disease Benign?

Authors:  Masaaki Uno; Hiroyuki Toi; Satoshi Hirai
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-06-26       Impact factor: 1.742

5.  Letter: Neurosurgical Triage in the Pandemic Era.

Authors:  Timothy Lucas
Journal:  Neurosurgery       Date:  2020-07-01       Impact factor: 4.654

6.  Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.

Authors:  Angelos G Kolias; Ellie Edlmann; Eric P Thelin; Diederik Bulters; Patrick Holton; Nigel Suttner; Kevin Owusu-Agyemang; Yahia Z Al-Tamimi; Daniel Gatt; Simon Thomson; Ian A Anderson; Oliver Richards; Peter Whitfield; Monica Gherle; Karen Caldwell; Carol Davis-Wilkie; Silvia Tarantino; Garry Barton; Hani J Marcus; Aswin Chari; Paul Brennan; Antonio Belli; Simon Bond; Carole Turner; Lynne Whitehead; Ian Wilkinson; Peter J Hutchinson
Journal:  Trials       Date:  2018-12-04       Impact factor: 2.279

7.  Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase.

Authors:  Ellie Edlmann; Eric P Thelin; Karen Caldwell; Carole Turner; Peter Whitfield; Diederik Bulters; Patrick Holton; Nigel Suttner; Kevin Owusu-Agyemang; Yahia Z Al-Tamimi; Daniel Gatt; Simon Thomson; Ian A Anderson; Oliver Richards; Monica Gherle; Emma Toman; Dipankar Nandi; Phillip Kane; Beatrice Pantaleo; Carol Davis-Wilkie; Silvia Tarantino; Garry Barton; Hani J Marcus; Aswin Chari; Antonio Belli; Simon Bond; Rafael Gafoor; Sarah Dawson; Lynne Whitehead; Paul Brennan; Ian Wilkinson; Angelos G Kolias; Peter J A Hutchinson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

8.  Prognosis of patients with operated chronic subdural hematoma.

Authors:  Jussi P Posti; Teemu M Luoto; Jussi O T Sipilä; Päivi Rautava; Ville Kytö
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

9.  Long-term excess mortality after chronic subdural hematoma.

Authors:  Minna Rauhala; Pauli Helén; Karri Seppä; Heini Huhtala; Grant L Iverson; Tero Niskakangas; Juha Öhman; Teemu M Luoto
Journal:  Acta Neurochir (Wien)       Date:  2020-03-07       Impact factor: 2.216

Review 10.  Adjuvant Corticosteroids With Surgery for Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis.

Authors:  Min Shi; Ling-Fei Xiao; Ting-Bao Zhang; Qing-Wen Tang; Wen-Yuan Zhao
Journal:  Front Neurosci       Date:  2021-12-08       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.